Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-02-12

Clinical Trial Update: At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension) [Phase 2]

View source ↗

Summary

Results posted for the TN-10 Extension, a Phase 2 trial in individuals at risk for Type 1 diabetes; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TZIELD (TEPLIZUMAB-MZWV)

Snippet

Sponsor: Provention Bio, a Sanofi Company | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2025-02-12